MannKind Ripe for Profit-Taking After Afrezza Approval

The FDA approved the drug maker's inhaled insulin drug, Afrezza. But with shares up 175% since April we'd sell.

The U.S. Food and Drug Administration early Friday approved an inhaled insulin called Afrezza, which frees the drug's manufacturer, MannKind (ticker: MNKD), to seek a commercial partner. Afrezza works with the two main types of diabetes, which affects about 29 million Americans, roughly a quarter of whom are treated with insulin.